fbpx
Jenny A

About Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

Full Show: A New CD38 Monocloncal Antibody Called Isatuximab Gets Closer to the Clinic, with Ravi Vij, MD, Washington University

Ravi Vij, MD Washington University Interview Date: February 6, 2019 Thanks to our episode sponsor Summary A new CD38 targeted monoclonal antibody is coming soon to the myeloma clinic. A new drug called isatuximab is making its way through the FDA approval process. Learn how it will be used in combinations, how it [...]

Read More

Gilead Drops Kite Multiple Myeloma CAR T Development

Gilead released fourth quarter results that removed an anti-BCMA cell therapy for multiple myeloma from it's pipeline, part of its $12 billion acquisition of Kite Pharma. The decision to drop the KITE-585-CAR T programs indicates the ever growing competition in the BCMA-targeted therapy for myeloma and represents a loss of $820M in investment.  [...]

Read More

Full Show: Myeloma Progress in 2018 and a Look to the Future in Multiple Myeloma with Dr. Robert Z. Orlowski, MD Anderson Cancer Center

Robert Z. Orlowski, MD, PhD MD Anderson Cancer Center  Interview Date: January 8, 2019 Thanks to our episode sponsor Summary There is a tremendous amount of progress being made in multiple myeloma. It was stunning to see the significant work being done in the field of myeloma at the recent American Society of [...]

Read More

Isatuximab Prolongs Progression Free Survival for Relapsed/Refractory Patients

A new monoclonal antibody targeting CD38 has been working its way through clinical trials. In the Phase 3 trial, Isatuximab was found to prolong progression free survival when combined with pomalidomide and dexamethasone compared to pomalidomide and dexamethasone alone.   The study, known as ICARIA-MM, enrolled 307 patients with relapsed/refractory myeloma. All participants had received [...]

Read More

Our Next Show: A New CD-38 Targeted Monoclonal Antibody Isatuximab with Dr. Ravi Vij, MD, Washington University, Wednesday, February 6 @ 2 pm Central

Wednesday, February 6, 2019 @ Noon Pacific, 1 pm Mountain, 2 pm Central, 3 pm Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer. A new monoclonal antibody called Isatuximab is advancing through clinical trials and is getting closer to FDA approval. This antibody targets CD38. Learn more from [...]

Read More

What Is Relapsed vs. Refractory Myeloma?

There are so many myeloma phrases, terminology and acronyms that things can get incredibly confusing. Let's talk about Relapsed Myeloma (sort of self explanatory) and Refractory Myeloma (need a refresher course on this one!). Relapsed Myeloma  According to Dr. Sagar Lonial, MD of the Winship Cancer Institute at Emory University, Relapsed Myeloma "specifically [...]

Read More

Clinical Trial: Overall Survival Lengthened for Relapsed/Refractory Myeloma Patients Using CLR 131 Cancer-Targeted Therapy

Myeloma patients who had relapsed after receiving both a proteasome inhibitor (like Velcade) and immunomodulator (like Revlimid) participated in a Phase I study of a new drug called CLR 131 and experienced an average 22 month overall survival.   While no head-to-head treatment comparisons have been performed, a 2016 article in the journal Bone Marrow Transplantation showed that [...]

Read More

The Stand Up To Cancer (SU2C) 2019 Scientific Summit (With a New Myeloma Dream Team)

Stand Up To Cancer (SU2C) hosted it's 9th annual Scientific Summit in Santa Monica, CA. SU2C is a non-profit funding important cancer research and was started in 2008 by a group of women who had been affected by cancer and believed that by merging the resources of the media and entertainment industries into a single operation [...]

Read More

Minimal Residual Disease Test Gets Medicare Coverage Approval for Myeloma Patients

The first minimal residual disease (MRD) test in multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) has received coverage approval for Medicare patients. The MRD test called ClonoSEQ, from Adaptive Biotechnologies can detect lower levels of multiple myeloma than traditional tests. MRD is a measurement of the remaining number of cancer cells that are present in a [...]

Read More

Clinical Trial: GVAX Vaccine with Revlimid To Extend Remission

A new GVAX vaccine is being used in a clinical trial for myeloma patients who have achieved good responses to therapy. The goal of the trial is to extend remissions and potentially deepen responses to a minimal residual disease (MRD) negative state. This vaccine was tested earlier in Phase I studies by Dr. Ivan Borrello [...]

Read More

Creating Your Most Valuable Plan (MVP) in Multiple Myeloma with David Winfield and Don Baylor Jr.

Being proactive about your myeloma care is essential in getting your best outcomes. The Myeloma Crowd interviewed Dave Winfield and Don Baylor Jr. to share how Don Baylor handled the highs and lows of multiple myeloma and the importance of creating your Most Valuable Plan. Learn more about this Amgen program on www.myelomaexplained.com and in [...]

Read More

Activating the Immune System to Eat Cancer Cells

Researchers at the University of Pennsylvania have found a way to encourage the immune system to eat cancer cells. Immune system cells called macrophages are large white blood cells that locate and 'eat" invader particles such as bacteria, viruses, fungi and parasites. According to the researchers, cancer has found ways to put these macrophages to [...]

Read More

Full Show: Personalized Myeloma Treatment Using 3D Tumor Modeling

Cesar Rodriguez, MD,  Wake Forest University  Interview Date: December 14, 2018 Thanks to our episode sponsor Summary Each myeloma patient’s tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations against your specific tumor [...]

Read More

Quad Therapy Clinical Trial Open for Relapsed Multiple Myeloma Using a Virus, Checkpoint Inhibitor, Carfilzomib and Dex

The destructive nature of viruses is now being applied to kill cancer cells. A new immuno-oncoloytic virus called pelareorep (Reolysin) is now being tested in a clinical trial in addition to three other drugs for relapsed multiple myeloma.  The harmless virus has been modified to infect and destroy cancer cells, but not normal cells. It [...]

Read More

ASH 2018: One Myeloma Transplant vs. Two? That is the Question

As long as I have a member of the myeloma patient community there has always been discussion of the role of transplant as well as the number of transplants.  Two prior studies had shown exactly opposite conclusions. Both study had differing designs, however both had elements of Velcade/Revlimid/Dex (VRD) induction, and as have previously found [...]

Read More

ASH 2018: New Advances in CAR T Studies with Damian Green, MD

At the recent American Society of Hematology meeting (ASH), Dr. Damian Green joined the Myeloma Crowd to share two CAR T studies he is working on.  He shared data on the Juno/Celgene study that showed rapid and good responses for patients with an average 11 lines of prior therapy for a BCMA targeted CAR T [...]

Read More

Full Show: Identifying and Killing Myeloma Cells That Cause Myeloma and Relapse with MCRI Award Winner Dr. Frank Zhan and Dr. Yogesh Jethava

Fenghauang (Frank) Zhan, PhD Yogesh Jethava, MD University of Iowa Interview Date: December 11, 2018 Thanks to our episode sponsor Summary What cells cause myeloma and why do patients relapse after treatment? Myeloma stem cells may be part of the answer.  Fenghauang (Frank) Zhan, PhD was recently selected as a Myeloma Crowd Research Initiative [...]

Read More

A New, Cheaper and More Useful Test to Detect Multiple Myeloma?

A new test called mass spectometry (MASS-FIX) is a quick, inexpensive and accurate way to diagnose and monitor the blood and urine of patients with multiple myeloma. Today, doctors use immunofixation, M-protein and light chain tests to test if patients have myeloma and how much of it they have. But these tests can vary and [...]

Read More

ASH 2018: Four-Drug Combo with Carfilzomib vs. Triplets Before Transplant

Graham Jackson, MD, PhD of the Northern Institute for Cancer Research in the United Kingdom (and colleagues) shared study results at the recent ASH 2018 comparing a four drug combination vs. a sequence of three drug combinations as induction therapy before stem cell transplant. The UK has an incredible amount of data about myeloma patients [...]

Read More

Day 9 of Myeloma Giving: Donate to Myeloma Research

Day 9 of Myeloma Giving: Donate to Myeloma Research From December 10 – 22, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, lengthen lives and makes lives [...]

Read More

Clinical Trial: Isatuximab with RVD for Newly Diagnosed Myeloma Patients

Revlimid, Velcade and dexamethasone (RVD) is a standard combination for newly diagnosed patients whether they are headed to transplant or not. A study is now open using a new CD38 monoclonal antibody called Isatuximab in combination with the "standard" therapy of RVD for newly diagnosed myeloma patients who do not qualify for a bone marrow [...]

Read More

ASH 2018: What to Do at Myeloma Relapse

Ajai Chari, MD, PhD of Mount Sinai spoke at the Friday session of the recent American Society of Hematology Meeting about strategies for myeloma relapse. He said that factors one should consider include age, fitness status, pre-existing medical conditions, how fast the myeloma numbers are rising and then the depth and duration of previous responses. [...]

Read More

Day 8 of Myeloma Giving: Sharing the Gift of Myeloma Crowd Round Tables and Live Patient Education

Day 8 of Myeloma Giving: Sharing the Gift of Myeloma Crowd Round Tables and Live Patient Education  From December 10 – 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift [...]

Read More

Day 6 of Myeloma Giving: The Science of Giving

Have you ever heard the saying “Only the good die young?”  Recent science, however, has proven that the opposite is true! The “good” are living longer, and science is finding empirical evidence that connects an attitude of giving with increased healing, longevity and overall happiness.  A new science of health and giving is emerging. Over [...]

Read More

Which Multiple Myeloma Patients May Do Well with the Measles Vaccine?

Multiple myeloma patient Stacy Erholtz's stunning response to the Mayo Clinic's measles vaccine in 2015 for her multi-relapsed multiple myeloma was a surprise to everyone, including Stacy. But when the vaccine was used in other myeloma patients, they did not see similar responses. Why? A new study by myeloma French researchers showed that myeloma patients with [...]

Read More

Day 5 of Myeloma Giving: Give the Gift of PROMISE Towards a Cure (Donate a Blood Sample)

Day 5 of Myeloma Giving: Give the Gift of PROMISE Towards a Cure (Donate a Blood Sample) From December 10 – 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift [...]

Read More

Perspectives from Tom Brokaw: From NBC to ASH

Tom Brokaw visited the recent American Society of Hematology (ASH) meeting and took some time to share his personal myeloma story.  He opened up about cancer,  how he feels about community and his love for our country. When Tom was diagnosed in 2013 at the age 74 he faced his diagnosis as he does everything [...]

Read More

Day 4 of Myeloma Giving: Give Gratitude for Multiple Myeloma Progress

Day 4 of Myeloma Giving: Give Gratitude for Multiple Myeloma Progress From December 10 – 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, [...]

Read More

Day 2 of Myeloma Giving: Share Your Myeloma Story

Day 2 of Myeloma Giving: Share your Myeloma Story From December 10 - 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, lengthen lives [...]

Read More

Our Next Show: MCRI Award Winner 3D Tumor Modeling Matching Myeloma Treatments with Your Tumor with Cesar Rodriguez, MD, Wake Forest University, Friday, Dec 14 @ 3 pm Eastern

Friday, December 14, 2018 @ Noon Pacific, 1 pm Mountain, 2 pm Central, 3 pm Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer. Each myeloma patient's tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the [...]

Read More

Can Cancer Medicine Be Precise AND Personal?

Precision medicine is a catch-phrase that is all the rage nowadays. It’s becoming clearer that medicine is not one-size-fits-all. For example, a treatment that helps shrink one person’s tumor or eases their arthritis symptoms doesn’t always work for somebody else. This is especially true in cancer, where a patient's experience is more than their genetic [...]

Read More

Day 1 of Myeloma Giving: I Don’t Have Melanoma, I Have Multiple Myeloma

Day 1 of Myeloma Giving: Share the gift of accurate information with your friends and family. I don't have the skin cancer melanoma, I have a blood cancer called multiple myeloma. From December 10 - 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and [...]

Read More

12 Days of Myeloma Giving with the Myeloma Crowd

During the hustle and bustle of the holiday season, I think we all know that the most appreciated gifts are those that we give from the heart. These gifts are usually simple acts of service - a listening ear, a smile or note of concern. Philosophers know that giving is key to our own sense of [...]

Read More

Our Next Show: Finding new Targets of Myeloma Stem Cells to Prevent Relapse with Frank Zhan, PhD and Yogesh Jethava, MD, University of Iowa, Tuesday, Dec 11 @ Noon Central

Tuesday, December 11, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1 pm Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer. Why do multiple myeloma patients relapse after myeloma therapy? Many myeloma experts believe that myeloma stem cells (or early progenitor cells before they become plasma [...]

Read More

Full Show: Creating an Immune System Signature to Gauge Myeloma Risk with MCRI Award Winner David Chung, MD, MSKCC

David Chung, MD, PhD Memorial Sloan Kettering Cancer Center Interview Date: November 19, 2018 Thanks to our episode sponsor Summary Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The patient’s immune system may be a key factor.   David Chung, MD, PhD [...]

Read More

A Tribute to Multiple Myeloma Advocate Eric Hansen

The Myeloma Crowd would like to honor the life and memory of myeloma patient advocate and Myeloma Crowd Patient Advisory Board member Eric Hansen, who died on Thursday in a single-car accident while driving in British Columbia. His accident could have been medically related but the details of the accident are unknown.  Eric Hansen (1943-11/27/2018) [...]

Read More

ASH 2018: Ninlaro as a Maintenance Therapy After Transplant

Dr. Meletios A Dimopoulos presented an abstract which compared the use of Ixaomib to a placebo for maintenance after a stem cell transplant.  This clinical trial was called Tourmaline-MM3, and was chosen as a top 5 abstract by 2 of the 4 doctors who had provided their "Best of the Best" abstracts. Abstract 301 - [...]

Read More

ASH 2018: Maintenance Therapy in Multiple Myeloma

The ASH conference has started with the early, "unofficial" sessions. Dr. Maria Victoria Mateos spoke at a Friday morning session about the role of maintenance therapy.  It has become obvious that in general, maintenance therapy is suggested for all patients and extends remission times. Dr. Mateos broadly described the use of maintenance therapy with immunomodulators [...]

Read More

Fortis Therapeutics Opens New Antibody Phase I Study in Multiple Myeloma Targeting CD46

San Diego-based Fortis Therapeutics is creating a new antibody drug conjugate for multiple myeloma and prostate cancer. The new drug will target CD46, not typically a target used in multiple myeloma. The study will open by the end of 2018.  FOR46 targets a new immune system receptor, CD46, which is highly expressed in several tumor [...]

Read More

What is the American Society of Hematology (ASH) Meeting and Why Does It Matter for Myeloma Patients? 

This weekend is the beginning of the American Society of Hematology (ASH) meeting. What is ASH and why does it matter to multiple myeloma patients?    ASH is the world’s largest hematology meeting where experts in blood cancers share their recent findings. At ASH, over 30,000 physicians and researchers converge on a city (this year [...]

Read More

Myeloma Crowd Research Initiative (MCRI) Announces Three Award Recipients

 Donate to the MCRI Today The first Myeloma Crowd Research Initiative (MCRI) successfully raised $500,000 for two immunotherapy research projects for high-risk myeloma (CAR T and T cell treatments). Now, the MCRI will fund research to match the right treatment with the right patient at the right time.  A small fraction of multiple myeloma [...]

Read More

Thalidomide Included in Induction and Maintenance Increases Survival in European Study

Thalidomide was the first immunomodulatory drug used for the treatment of multiple myeloma. It went on to become the base of a series of multiple myeloma drugs offered by Celgene Corporation who now produces Thalomid, Revlimid and Pomalyst -  all variations of this immunomodulatory drug class.  In a recent study, Thalidomide used as induction therapy [...]

Read More

Our Next Show: Discovering an Immune System Signature for Multiple Myeloma Patients with MCRI Award Winner David Chung, MD, PhD, MSKCC

Monday, November 19, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1 pm Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The patient's immune system may be [...]

Read More

Faster CAR T Production = Better Results in Blood Cancers

Carl June, MD of the University of Pennsylvania and colleagues announced in a recent paper that faster production of the CAR T cells improves the strength of the treatment.  The CD19 CAR T therapy has been in development for many years, launching initially in leukemia. This new therapy holds significant promise for all blood cancer [...]

Read More

FDA Approves Empliciti with Pomalidomide and Dexamethasone for Relapsed Multiple Myeloma

Empliciti (elotuzumab) was approved yesterday by the FDA for use with pomalidomide and dexamethasone in relapsed myeloma, according to a press release by Bristol-Myers Squibb. The combination was approved for patients who relapsed after two prior treatments including lenalidomide and a proteasome inhibitor.  The immunotherapy was tested in a study called the ELOQUENT-3 trial. In [...]

Read More

Full Show: Racial Disparities in Multiple Myeloma with Ashraf Badros, MD, University of Maryland

Ashraf Badros, MD University of Maryland Interview Date: October 3, 2018 Thanks to our episode sponsor, Celgene Corporation. Summary African Americans are more than twice as likely to develop multiple myeloma. But they are not getting the longest life possible for a variety of reasons. How can they obtain better outcomes and live [...]

Read More

New Drug for Myeloma Targeting Myeloma Cell Survival Pathway

A new pathway to stop myeloma progression is being studied with a new drug, according to a recent report by UK multiple myeloma specialists.  A pathway that helps myeloma cells survive, called nuclear factor (NF)‐κB, is activated in all cases of multiple myeloma. Many companies have tried to target this pathway over the last 30 [...]

Read More

Can Comedy Help Cure Cancer? Spellchek Features HealthTree on a Viral Video.

There's nothing funny about cancer, but what if comedy could help get out an important message for multiple myeloma patients? That was the spark of an idea behind comedian Dave Vance's brilliant new video on HealthTree featured on his Spellchek channel. His question is valid. Why haven't we cured cancer yet? And why isn't technology [...]

Read More